Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Takeda, PRA to Launch JV in Japan to Take Over 140 Employees
February 16, 2017
- Ono Looks for New Growth through Opdivo Despite NHI Price Cut: President
February 16, 2017
- Bristol-Myers Looks to Crack into Genotype 1 Hep C Market as Ximency Clears Resistance Mutation Hurdle
February 15, 2017
- Keytruda Now Available in Japan
February 15, 2017
- AbbVie’s 8-Week Hep C Therapy Filed in Japan
February 15, 2017
- Otsuka Aims for Abilify Maintena’s 30% Share in LAI Antipsychotic Market
February 15, 2017
- Otsuka’s 2016 Earnings Falter as Abilify Sales Dive 70%
February 15, 2017
- Bisphosphonates Grab Top Share, PTH Preparations Expand in FY2015 Osteoporosis Market: Report
February 14, 2017
- Test Urine Copper in Pregnant Women Taking Nobelzin: Nobelpharma
February 14, 2017
- Maruho to Hand Over Joint Disorder Med to Ayumi
February 14, 2017
- Otsuka Aims to Resubmit NDA for Sensor-Embedded Abilify in US by Mid-Year
February 14, 2017
- Sawai Gets FDA Nod for Livalo Generic
February 13, 2017
- Daiichi Sankyo Shutters Research Unit Asubio amid R&D Rejig
February 13, 2017
- Novartis Seeks Pediatric CML Indication for Tasigna
February 13, 2017
- Bayer Yakuhin Ramping Up Digital Transformation: New President
February 10, 2017
- Harvoni No. 1 Drug in Japan in 2016 with Sales of 296 Billion Yen, More than Any Other Drug Over Past 10 Years: IMS Japan
February 10, 2017
- Sandoz Looks to Double Japan Sales by 2022
February 9, 2017
- Ethical Drug Sales Down 8.2% in December: Crecon
February 8, 2017
- OrphanPacific to Distribute Diazoxide from April
February 7, 2017
- Akihisa Nabeshima to Become Teijin Pharma President
February 7, 2017
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…